{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:48:02Z","timestamp":1776185282371,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen France SAS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40120-024-00674-x","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:56:40Z","timestamp":1731311800000},"page":"177-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing\u2013Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04221191","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pierre","family":"Labauge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cr\u00e9ange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyne","family":"Nouvet-Gire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Pedespan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Heinzlef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Texier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Gros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7744-4207","authenticated-orcid":false,"given":"Marta","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"1","key":"674_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"key":"674_CR2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS, France. 2023. https:\/\/www.atlasofms.org\/fact-sheet\/france. Accessed Aug 28, 2023."},{"key":"674_CR3","unstructured":"United States Food and Drug Administration. TECFIDERA\u00ae (dimethyl fumarate) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204063s029lbl.pdf. Accessed May\u00a025, 2023."},{"key":"674_CR4","unstructured":"European Medicines Agency. TECFIDERA\u00ae (dimethyl fumarate) summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecfidera-epar-product-information_en.pdf. Accessed May\u00a025, 2023."},{"key":"674_CR5","unstructured":"European Medicines Agency. AVONEX\u00ae (interferon beta-1a) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avonex-epar-product-information_en.pdf. Accessed Nov 22, 2023."},{"key":"674_CR6","unstructured":"European Medicines Agency. OCREVUS\u00ae (ocrelizumab) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Accessed Nov 22, 2023."},{"key":"674_CR7","unstructured":"European Medicines Agency. TYSABRI\u00ae (natalizumab) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf. Accessed Nov 22, 2023."},{"key":"674_CR8","unstructured":"European Medicines Agency. KESIMPTA\u00ae (ofatumumab) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed Nov 22, 2023."},{"key":"674_CR9","unstructured":"European Medicines Agency. AUBAGIO\u00ae (teriflunomide) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf. Accessed Nov 22, 2023."},{"key":"674_CR10","unstructured":"European Medicines Agency. GILENYA\u00ae (fingolimod) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf. Accessed Nov 22, 2023"},{"key":"674_CR11","unstructured":"United States Food and Drug Administration. COPAXONE\u00ae (glatiramer acetate) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020622s116lbl.pdf. Accessed Nov 22, 2023."},{"key":"674_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104125","volume":"68","author":"S Peterson","year":"2022","unstructured":"Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for multiple sclerosis: a review. Mult Scler Relat Disord. 2022;68: 104125.","journal-title":"Mult Scler Relat Disord"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"674_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase\u00a03 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"2","key":"674_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2017","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253\u201365.","journal-title":"Mult Scler"},{"issue":"12","key":"674_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase\u00a03 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"12","key":"674_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077\u201387.","journal-title":"Clin Ther"},{"issue":"10","key":"674_CR18","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674\u201389.","journal-title":"Lancet Healthy Longev"},{"key":"674_CR19","unstructured":"Palmer A, Sarkar S. IQVIA white paper. Design and refine: make patient support programs work for your patients. 2021. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/asia-pacific\/white-papers\/design-and-refine.pdf. Accessed Sept 28, 2023."},{"issue":"3","key":"674_CR20","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1097\/JNN.0b013e31828a4161","volume":"45","author":"T Kohlmann","year":"2013","unstructured":"Kohlmann T, Wang C, Lipinski J, et al. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status. J Neurosci Nurs. 2013;45(3):E3-14.","journal-title":"J Neurosci Nurs"},{"issue":"6","key":"674_CR21","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s12325-020-01349-3","volume":"37","author":"F Lenz","year":"2020","unstructured":"Lenz F, Harms L. The impact of patient support programs on adherence to disease-modifying therapies of patients with relapsing-remitting multiple sclerosis in Germany: a non-interventional, prospective study. Adv Ther. 2020;37(6):2999\u20133009.","journal-title":"Adv Ther"},{"key":"674_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2147\/PPA.S59496","volume":"8","author":"J Roche","year":"2014","unstructured":"Roche J, McCarry Y, Mellors K. Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adher. 2014;8:805\u201311.","journal-title":"Patient Prefer Adher"},{"issue":"9","key":"674_CR23","first-page":"1273","volume":"27","author":"J Mardan","year":"2021","unstructured":"Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27(9):1273\u201395.","journal-title":"J Manag Care Spec Pharm"},{"key":"674_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211031099","volume":"14","author":"G Zanga","year":"2021","unstructured":"Zanga G, Drzewiscki E, Tagliani P, Smietniansky M, Esnaola y Rojas MM, Caruso D. Predictors of adherence and persistence to disease-modifying therapies in multiple sclerosis. Ther Adv Neurol Disord. 2021;14: 17562864211031099.","journal-title":"Ther Adv Neurol Disord"},{"key":"674_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104866","volume":"77","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: a claims analysis of real-world data. Mult Scler Relat Disord. 2023;77: 104866.","journal-title":"Mult Scler Relat Disord"},{"issue":"21","key":"674_CR26","first-page":"1044","volume":"30","author":"X Girerd","year":"2001","unstructured":"Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic [article in French]. Presse Med. 2001;30(21):1044\u20138.","journal-title":"Presse Med"},{"issue":"10","key":"674_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"key":"674_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"674_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3917\/bupsy.515.0471","volume":"515","author":"G Delelis","year":"2011","unstructured":"Delelis G, Christophe V, Berjot S, Desombre C. Strat\u00e9gies de r\u00e9gulation \u00e9motionnelle et de coping: quels liens? Bull Psychol. 2011;515(5):471\u20139.","journal-title":"Bull Psychol"},{"issue":"2","key":"674_CR30","first-page":"89","volume":"48","author":"F Cousson-G\u00e9lie","year":"1998","unstructured":"Cousson-G\u00e9lie F, Taytard A, Quintard B. L\u2019\u00e9valuation des strat\u00e9gies de coping chez des patients asthmatiques. Eur Rev Appl Psychol. 1998;48(2):89\u201395.","journal-title":"Eur Rev Appl Psychol"},{"issue":"8","key":"674_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1177\/1359105310364438","volume":"15","author":"F Cousson-G\u00e9lie","year":"2010","unstructured":"Cousson-G\u00e9lie F, Cosnefroy O, Christophe V, et al. The Ways of Coping Checklist (WCC): validation in French-speaking cancer patients. J Health Psychol. 2010;15(8):1246\u201356.","journal-title":"J Health Psychol"},{"key":"674_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104080","volume":"67","author":"MT Thompson","year":"2022","unstructured":"Thompson MT, Virginia D, Nick B, et al. Adherence and discontinuation rates in patients on Tecfidera\u2122 (dimethyl fumarate): long-term Canadian experience from the Biogen ONE\u2122 support program. Mult Scler Relat Disord. 2022;67: 104080.","journal-title":"Mult Scler Relat Disord"},{"key":"674_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CEOR.S130334","volume":"9","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251\u201360.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"674_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.36469\/jheor.2022.33288","volume":"9","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Sheinson D, Bonine NG. The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis. J Health Econ Outcomes Res. 2022;9(1):111\u20136.","journal-title":"J Health Econ Outcomes Res"},{"key":"674_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104615","volume":"72","author":"M Jo\u017eef","year":"2023","unstructured":"Jo\u017eef M, Locatelli I, Brecl Jakob G, Rot U, Kos M. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate. Mult Scler Relat Disord. 2023;72: 104615.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"674_CR36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","volume":"7","author":"ND Chiaravalloti","year":"2008","unstructured":"Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139\u201351.","journal-title":"Lancet Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00674-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:18:54Z","timestamp":1737821934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00674-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pierre Labauge has received financial support for participation in conferences and laboratory fees from Biogen, Bristol Myers Squibb, Merck, Novartis, Sanofi Genzyme, and Teva. Alain Cr\u00e9ange has received financial support for research from Biogen, GeNeuro, MedDay, Novartis, Octapharma, and Roche and has received honoraria from Biogen, GeNeuro, Novartis, and Roche. Thibault Moreau has received research support and scientific consultant fees from Biogen, Merck, Novartis, Roche, and Sanofi. Jocelyne Nouvet-Gire, Nathalie Texier, and Mikel Martinez have no conflicts of interest to disclose. Bernard Pedespan has received scientific consultant fees from AbbVie, Angelini, Eli Lilly and Company, Merck, Novartis, and Sanofi. Olivier Heinzlef has received consulting and lecture fees from Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, and Teva, travel grants from Biogen, Genzyme, Merck Serono, Novartis, and Teva, and research support from Merck, Novartis, and Roche. Marilyn Gros and Marta Ruiz are employees of and may own stock in Biogen. Catherine Marti was an employee of and may have owned stock in\u00a0Biogen at the time that the study was conducted and is currently an employee of LifeScan France SAS. Giovanni Castelnovo has received financial support for participation in conferences and laboratory fees from AbbVie, Biogen, Bristol Myers Squibb, Janssen, Merck, Merz, Novartis, Roche, Sanofi Genzyme, and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the International Council for Harmonisation guidelines, the ethical principles outlined in the Declaration of Helsinki and\/or, where applicable, the European Directive 2001\/20 in relation to Good Clinical Practice. The study was submitted to and approved by a French Committee for the Protection of Persons (Comit\u00e9 de Protection des Personnes) on July 11, 2019. All patients provided oral informed consent at M0 regarding TEC-ADHERE and authorization to use protected health information. For OroSEP, patients provided written consent to participate in the PSP at DMF initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}